Abstract
Purpose: To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV). Methods: A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5 mg were administered intravitreally without complications. Results: After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed. Conclusions: Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.
| Original language | English |
|---|---|
| Journal | Journal Francais d'Ophtalmologie |
| Volume | 36 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2013 |
Fingerprint
Keywords
- Adult onset foveomacular vitelliform dystrophy
- Age-related macular degeneration
- Fluorescein angiography
- Indocyanine green angiography
- Lucentis
- Ranibizumab
- Retinal angiomatous proliferation
- Retinal-choroidal anastomosis
- Spectral-domain optical coherence tomography
- Type 3 choroidal neovascularization
- Vitelliform macular dystrophy
ASJC Scopus subject areas
- Ophthalmology
Cite this
Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy. / Querques, G.; Querques, L.; Leveziel, N.; Bandello, F.; Souied, E. H.
In: Journal Francais d'Ophtalmologie, Vol. 36, No. 1, 01.2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy
AU - Querques, G.
AU - Querques, L.
AU - Leveziel, N.
AU - Bandello, F.
AU - Souied, E. H.
PY - 2013/1
Y1 - 2013/1
N2 - Purpose: To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV). Methods: A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5 mg were administered intravitreally without complications. Results: After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed. Conclusions: Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.
AB - Purpose: To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV). Methods: A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5 mg were administered intravitreally without complications. Results: After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed. Conclusions: Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.
KW - Adult onset foveomacular vitelliform dystrophy
KW - Age-related macular degeneration
KW - Fluorescein angiography
KW - Indocyanine green angiography
KW - Lucentis
KW - Ranibizumab
KW - Retinal angiomatous proliferation
KW - Retinal-choroidal anastomosis
KW - Spectral-domain optical coherence tomography
KW - Type 3 choroidal neovascularization
KW - Vitelliform macular dystrophy
UR - http://www.scopus.com/inward/record.url?scp=84873709484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873709484&partnerID=8YFLogxK
U2 - 10.1016/j.jfo.2012.04.013
DO - 10.1016/j.jfo.2012.04.013
M3 - Article
C2 - 23218864
AN - SCOPUS:84873709484
VL - 36
JO - Journal Francais d'Ophtalmologie
JF - Journal Francais d'Ophtalmologie
SN - 0181-5512
IS - 1
ER -